Key Points
- Major shareholder Jorey Chernett sold 109,436 Exagen shares at an average $4.65, worth about $508,877, reducing his stake by 4.06% to 2,587,504 shares.
- Exagen reported a quarterly loss of $0.25 per share, missing the $0.18 loss analysts expected, while revenue of $18.42 million slightly exceeded forecasts.
- Shares traded at $4.13 on Friday. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $9.88.
Exagen Inc. (NASDAQ:XGN - Get Free Report) major shareholder Jorey Chernett sold 58,068 shares of the business's stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $4.08, for a total transaction of $236,917.44. Following the completion of the sale, the insider directly owned 2,529,436 shares of the company's stock, valued at $10,320,098.88. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Thursday, November 12th, Jorey Chernett sold 109,436 shares of Exagen stock. The stock was sold at an average price of $4.65, for a total transaction of $508,877.40.
- On Wednesday, November 11th, Jorey Chernett purchased 71,315 shares of Exagen stock. The shares were acquired at an average price of $5.23 per share, for a total transaction of $372,977.45.
- On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total transaction of $69,167.10.
- On Tuesday, November 10th, Jorey Chernett acquired 7,085 shares of Exagen stock. The stock was acquired at an average cost of $5.26 per share, with a total value of $37,267.10.
- On Monday, November 9th, Jorey Chernett acquired 8,500 shares of Exagen stock. The stock was acquired at an average price of $6.35 per share, with a total value of $53,975.00.
- On Monday, October 19th, Jorey Chernett acquired 14,000 shares of Exagen stock. The stock was acquired at an average price of $7.46 per share, with a total value of $104,440.00.
Exagen Stock Down 6.3%
Exagen stock traded down $0.28 during mid-day trading on Friday, hitting $4.13. 3,356,140 shares of the company's stock were exchanged, compared to its average volume of 581,895. The company has a current ratio of 3.46, a quick ratio of 3.18 and a debt-to-equity ratio of 1.73. The stock has a market cap of $105.36 million, a P/E ratio of -5.51 and a beta of 2.25. Exagen Inc. has a 1-year low of $2.59 and a 1-year high of $9.28. The stock has a 50 day moving average of $7.71 and a two-hundred day moving average of $5.13.
Exagen (NASDAQ:XGN - Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. The company had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.34 million. As a group, analysts anticipate that Exagen Inc. will post -0.71 EPS for the current fiscal year.
Trending Headlines about Exagen
These are some of the XGN headlines that stood out recently:
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Exagen in a report on Wednesday, November 4th. Wall Street Zen lowered Exagen from a "hold" rating to a "sell" rating in a report on Saturday. Canaccord Genuity Group reduced their target price on Exagen from $11.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday. B. Riley Financial assumed coverage on Exagen in a research report on Friday, September 11th. They set a "buy" rating and a $12.00 target price for the company. Finally, TD Cowen increased their price target on Exagen from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.88.
Get Our Latest Research Report on Exagen
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Corient Private Wealth LP acquired a new position in Exagen during the 2nd quarter worth $52,000. Penbrook Management LLC acquired a new stake in shares of Exagen in the third quarter valued at about $92,000. Calamos Advisors LLC acquired a new stake in shares of Exagen in the third quarter valued at about $94,000. Bank of New York Mellon Corp acquired a new stake in shares of Exagen in the second quarter valued at about $97,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Exagen by 137.4% in the first quarter. Dimensional Fund Advisors LP now owns 62,571 shares of the company's stock worth $188,000 after purchasing an additional 36,213 shares during the period. Institutional investors own 75.25% of the company's stock.
Exagen Company Profile
(
Get Free Report)
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company's AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
